You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

co-mutation

Showing 1 - 25 of 8,286
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11

Recruiting
  • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
  • Montpellier, France
  • +7 more
Dec 19, 2022

NSCLC Trial in China (JAB 21822)

Recruiting
  • Non-small Cell Lung Cancer
  • JAB 21822
  • Beijing, Beijing, China
  • +20 more
Sep 26, 2022

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Pancreatic Cancer Trial in Seoul (cell free DNA in blood, genetic mutation in tissue)

Recruiting
  • Pancreatic Cancer
  • cell free DNA in blood, genetic mutation in tissue
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 2, 2022

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

Real-world Data of Afatinib Treatment in First-line Setting and

Active, not recruiting
  • Non-squamous, Non-Small Cell Lung Cancer
  • Tokyo, Japan
    Nippon Boehringer Ingelheim Co., Ltd.
Jan 9, 2023

NSCLC Trial in Changsha, Shanghai, Hangzhou (H002 capsule)

Recruiting
  • Non-small Cell Lung Cancer
  • H002 capsule
  • Changsha, Hunan, China
  • +2 more
Sep 20, 2022

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
May 23, 2023

Leber Congenital Amaurosis Trial in Shanghai (HG004)

Recruiting
  • Leber Congenital Amaurosis
  • HG004
  • Shanghai, Shanghai, China
    Xinhua Hospital affiliated with Shanghai Jiao Tong UniversitySch
Oct 12, 2023

Advanced Solid Tumor Trial in Beijing (YK0901 cells)

Not yet recruiting
  • Advanced Solid Tumor
  • YK0901 cells
  • Beijing, China
    Department of GI Oncology, Peking University Cancer Hospital
Jun 27, 2023

Patogenic Mutation in 5 Genes

Completed
  • Colorectal Cancer
  • +5 more
  • co-occuring mutation
  • Jakarta, ALL, Indonesia
    Vania Myralda Giamour Marbun
Jul 21, 2021

Solid Tumor Trial in Hangzhou (D-1553, IN10018)

Not yet recruiting
  • Solid Tumor
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital, Cancer Hospital of the University of C
Aug 5, 2022

Practical Usability of EGFR Mutation Detection in ctDNA From

Recruiting
  • Lung Neoplasms
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Aug 23, 2021

    Adenocarcinoma of Lung Trial in Beijing (Furmonertinib)

    Not yet recruiting
    • Adenocarcinoma of Lung
    • Beijing, China
      Peking University People's Hospital
    Oct 3, 2021

    Co-existing Mutations on Sorafenib Maintenance Therapy After

    Completed
    • Acute Myeloid Leukemia
    • +2 more
    • Guangzhou, Guangdong, China
      Department of Hematology,Nanfang Hospital, Southern Medical Univ
    May 30, 2022

    Lung Cancer, EGFR Gene Mutation Trial (Almonertinib)

    Not yet recruiting
    • Lung Cancer
    • EGFR Gene Mutation
    • (no location specified)
    May 6, 2021

    Familial Alzheimer (FAD), PSEN1 Mutation Trial in Japan (Bromocriptine, Placebos)

    Completed
    • Familial Alzheimer Disease (FAD)
    • PSEN1 Mutation
    • Nagoya, Aichi, Japan
    • +7 more
    Mar 29, 2022

    Osimertinib for Patients With Non-Small Cell Lung Cancer

    Not yet recruiting
    • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    • EGFR Exon20 Insertion Mutations
    • Baoding, China
    • +23 more
    Aug 23, 2022

    NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation Trial in Nanchang (Almonertinib, Bevacizumab)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Nanchang, Jiangxi, China
      The Second Afiliated Hospital of Nanchang University
    Jun 26, 2021

    Non Small Cell Lung Cancer Trial in Shijiazhuang, Hohhot, Tianjin (Anlotinib Plus Icotinib)

    Completed
    • Non Small Cell Lung Cancer
    • Anlotinib Plus Icotinib
    • Shijiazhuang, Hebei, China
    • +4 more
    Mar 11, 2021

    Lung Cancer Trial (Almonertinib)

    Not yet recruiting
    • Lung Cancer
    • (no location specified)
    Apr 8, 2021

    NSCLC Trial (Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

    Recruiting
    • Non-small Cell Lung Cancer
    • Changchun, China
    • +25 more
    Aug 26, 2022

    Non-small Cell Lung Carcinoma Trial in China (Almonertinib, Pemetrexed, Cisplatin)

    Enrolling by invitation
    • Non-small Cell Lung Carcinoma
    • Beijing, Beijing, China
    • +33 more
    Feb 8, 2022

    Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation Trial in Shanghai (Fluzoparib;

    Recruiting
    • Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
    • Fluzoparib; Apatinib
    • +2 more
    • Shanghai, China
      Jiangsu HengRui Medicine Co., Ltd.
    Aug 6, 2020